U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813742) titled '18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma' on Dec. 24, 2024.
Brief Summary: The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Study Start Date: May 01, 2023
Study Type: OBSERVATIONAL
Condition:
Pheochromocytoma
Intervention:
DRUG: 18F-MFBG
Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Recruitment Status: RECRUITING
Sponsor: First Affiliated Hospital of Zhejiang Univers...